NCT06611904View on ClinicalTrials.gov

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

February 5, 2022

Study Completion Date

December 15, 2024

Conditions
Urine Albumin (UAlb)GlycocalyxArterial Stiffness
Interventions
DRUG

Dulaglutide

Combined treatment with dulaglutide and dapagliflozin

DRUG

DPP-4 Inhibitors

DPP-4i treatment as an add-on to metformin

Trial Locations (1)

12462

Attikon University General Hospital, Chaïdári

All Listed Sponsors
lead

Attikon Hospital

OTHER

NCT06611904 - The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria | Biotech Hunter | Biotech Hunter